Biotech investment is the new front in the U.S.-China trade fight
The Treasury Department’s proposed restrictions on U.S. investment in Chinese biopharma collide with Beijing’s new export curbs on cutting edge biotech innovations.
The Treasury Department’s proposed restrictions on U.S. investment in Chinese biopharma collide with Beijing’s new export curbs on cutting edge biotech innovations.
